Ramachandran A, Snehalatha C, Satyavani K, Sivasankari S, Vijay V
Diabetes Research Centre, M.V. Hospital for Diabetes & WHO Collaborating Centre for Research, Education and Training in Diabetes, 5, Main Road, Royapuram, Chennai 600 013, India.
Diabetes Res Clin Pract. 2007 May;76(2):215-8. doi: 10.1016/j.diabres.2006.08.009. Epub 2006 Sep 18.
In this study, we assessed for the prevalence of metabolic syndrome (MetS) in the cohort of subjects with impaired glucose tolerance (IGT) in the Indian Diabetes Prevention Programme and studied whether the syndrome enhanced the conversion to diabetes.
Effectiveness of lifestyle modification (LSM), metformin (Met) and LSM plus Met was tested in a randomised, controlled primary prevention study in subjects with IGT n=502 (M:W 397:105) at a median follow up of 30 months. Baseline prevalence of MetS was calculated using the WHO criteria. Insulin resistance (IR) was calculated using homeostasis model assessment (HOMA) method.
MetS was present in 233 subjects (46.4%; 95% CI 41.9-50.9) in the total group, in men (n=168; 42.3%; 95% CI 37.4-47.3) and in women (n=65; 61.9%; 95% CI 51.9-71.2) (men versus women chi(2)=12.8, p=0.0005). Insulin resistance (HOMA-IR>or=4.1) was present in 69.1% with no gender difference. IR increased proportionately with increasing number of abnormalities, in IGT (39.8%), IGT plus one abnormality (56.5%) and IGT plus any two or more abnormalities (69.1%) (Mantel Haenszel chi(2)=22.8, p<0.0001). Incidence of diabetes was similar in subjects with (40.3%) (n=94/233) or without (40.1%) (n=108/269) MetS (p=0.97). Cox's regression analysis confirmed that MetS did not enhance the conversion rate of IGT to diabetes both in the control (HR=0.88, 95% CI 0.53-1.47, p=0.63) and in the total group (HR=1.02, 95% CI 0.78-1.35, p=0.88), after correcting for effects of intervention.
Prevalence of MetS is high in Asian Indian IGT subjects, especially in women. However, it did not influence the rate of conversion of IGT to diabetes.
在本研究中,我们评估了印度糖尿病预防项目中糖耐量受损(IGT)受试者队列中代谢综合征(MetS)的患病率,并研究该综合征是否会增加糖尿病的转化率。
在一项随机对照的一级预防研究中,对502名IGT受试者(男∶女 = 397∶105)进行了中位随访30个月,测试了生活方式改变(LSM)、二甲双胍(Met)以及LSM加Met的有效性。采用世界卫生组织标准计算MetS的基线患病率。使用稳态模型评估(HOMA)方法计算胰岛素抵抗(IR)。
在全部受试者中,233名受试者(46.4%;95%可信区间41.9 - 50.9)存在MetS,男性(n = 168;42.3%;95%可信区间37.4 - 47.3)和女性(n = 65;61.9%;95%可信区间51.9 - 71.2)中也存在MetS(男性与女性比较,χ² = 12.8,p = 0.0005)。胰岛素抵抗(HOMA-IR≥4.1)的发生率为69.1%,无性别差异。在IGT(39.8%)、IGT加一项异常(56.5%)以及IGT加两项或更多异常(69.1%)中,IR随异常数量增加而呈比例增加(Mantel Haenszel χ² = 22.8,p < 0.0001)。有MetS的受试者(40.3%)(n = 94/233)和无MetS的受试者(40.1%)(n = 108/269)糖尿病发生率相似(p = 0.97)。校正干预效应后,Cox回归分析证实,在对照组(HR = 0.88,95%可信区间0.53 - 1.47,p = 0.63)和全部受试者组(HR = 1.02,95%可信区间0.78 - 1.35,p = 0.88)中,MetS均未增加IGT向糖尿病的转化率。
亚洲印度IGT受试者中MetS患病率较高,尤其是女性。然而,它并未影响IGT向糖尿病的转化率。